BLU-945 clinical trial

[Product Name] BLU-945

[Drug Type] Fourth-generation Oral EGFR Tyrosine Kinase Inhibitor (TKI)

[Specification] 100 mg × 28 tablets

[Manufacturer] Indar Pharmaceutical

As a fourth-generation EGFR-targeted therapy, BLU-945 offers a new treatment option for patients with advanced non-small cell lung cancer (NSCLC) by precisely inhibiting multiple mutation types. Since BLU-945 has not yet been officially launched on the market, the product we are making available ahead of the official release remains in the clinical trial stage. It is intended as an emergency treatment for patients who have developed resistance to third-generation therapies—such as Osimertinib—and for whom no other treatment options currently exist. If you have not developed resistance to previous generations of these therapies, please do not purchase this product.

[R&D and Clinical Progress]

Clinical Trials: Currently in Phase III clinical development (the SYMPHONY trial). Early data indicate efficacy in patients harboring triple mutations (L858R/T790M/C797S) and demonstrate good tolerability.

Potential Advantages: Compared to Osimertinib (a third-generation EGFR-TKI), BLU-945 exhibits stronger inhibitory activity against the C797S resistance mutation, potentially serving as a new treatment option following the development of drug resistance.

[Indications]

Indicated for advanced or metastatic non-small cell lung cancer (NSCLC) that is positive for EGFR mutations, particularly in patients who have developed drug resistance (e.g., T790M or C797S mutations) following treatment with other EGFR-targeted therapies.

[Dosage and Administration]

Recommended Dosage:

The standard dose is 100 mg, taken orally once daily after a meal to minimize gastrointestinal side effects.

Administration Method:

Oral tablets; must be swallowed whole. [Mechanism of Action]

BLU-945 acts by selectively inhibiting the activity of mutant EGFR proteins, thereby blocking the proliferative signaling pathways within tumor cells. It demonstrates particularly potent cytotoxic activity against cancer cells harboring the T790M/C797S compound mutation, exhibiting greater efficacy than previous generations of EGFR-TKIs.

[Adverse Reactions and Management]

Common Side Effects and Management Recommendations:

Nausea, Vomiting, Diarrhea: Adjust diet (avoid spicy or greasy foods); use antiemetics or antidiarrheals as necessary.

Fatigue, Headache: Ensure adequate rest; avoid strenuous physical activity.

Rash, Dry Skin: Use gentle moisturizers; avoid prolonged sun exposure.

Severe Side Effects and Management Strategies:

Elevated Liver Enzymes (Grade 3 or higher): Temporarily suspend medication; monitor liver function; upon recovery, adjust dosage or permanently discontinue the drug.

Allergic Reactions (e.g., difficulty breathing): Immediately discontinue medication and seek medical attention; antiallergic treatment may be required.

[Precautions and Contraindications]

Contraindicated Populations:

Pregnant women and breastfeeding women (potential risk to the fetus or infant);

Patients with severe hepatic or renal impairment (risk-benefit assessment required).

Drug Interactions:

Avoid concomitant use with potent CYP3A4 inhibitors (e.g., clarithromycin), as this may increase plasma concentrations of BLU-945. Monitoring Requirements:

Periodically monitor liver function, complete blood count (CBC), and tumor markers; perform imaging assessments every 2–3 months.

[Storage Conditions]

Store sealed in the original packaging, protected from light and moisture. Frozen storage at -20°C is recommended (note: references to room-temperature storage in some documentation require further verification).

Product Specifications

Product Name: BLU-945 (BLU-945); 4th-Generation EGFR-Targeted Therapy (Used following Osimertinib resistance)

Common Name: BLU-945

Composition: BLU-945

Dosage Form: Capsules

Specification: 100 mg × 28 capsules

Manufacturer: Indar Pharmaceutical

Indications: Indicated for advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR mutations, particularly for patients who have developed resistance (e.g., T790M or C797S mutations) following treatment with other EGFR-targeted therapies.

Dosage and Administration:The standard dose is 100 mg, taken orally once daily after meals to minimize gastrointestinal side effects.